Fifth Third Wealth Advisors LLC Purchases 107 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Fifth Third Wealth Advisors LLC lifted its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 27.0% in the third quarter, HoldingsChannel reports. The fund owned 504 shares of the biopharmaceutical company’s stock after buying an additional 107 shares during the period. Fifth Third Wealth Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $530,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in REGN. International Assets Investment Management LLC raised its position in shares of Regeneron Pharmaceuticals by 86,013.3% during the third quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company’s stock worth $926,078,000 after acquiring an additional 879,916 shares during the last quarter. Price T Rowe Associates Inc. MD increased its holdings in Regeneron Pharmaceuticals by 25.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 902,613 shares of the biopharmaceutical company’s stock valued at $868,757,000 after purchasing an additional 184,561 shares during the last quarter. Swedbank AB bought a new stake in Regeneron Pharmaceuticals in the first quarter valued at about $129,257,000. Epoch Investment Partners Inc. bought a new stake in Regeneron Pharmaceuticals in the first quarter valued at about $99,667,000. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its holdings in Regeneron Pharmaceuticals by 23.8% in the second quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 500,274 shares of the biopharmaceutical company’s stock valued at $525,804,000 after purchasing an additional 96,266 shares during the last quarter. Institutional investors own 83.31% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently commented on REGN. Evercore ISI dropped their price objective on Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating for the company in a report on Thursday, October 24th. Barclays lowered their price target on Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating for the company in a report on Friday, November 1st. Leerink Partners restated a “market perform” rating and issued a $1,077.00 price target (down from $1,175.00) on shares of Regeneron Pharmaceuticals in a report on Tuesday, September 24th. Royal Bank of Canada lowered their price target on Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating for the company in a report on Friday, November 1st. Finally, Oppenheimer lowered their price target on Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating for the company in a report on Wednesday, November 6th. One research analyst has rated the stock with a sell rating, four have given a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $1,099.55.

Regeneron Pharmaceuticals Stock Performance

REGN opened at $743.35 on Thursday. Regeneron Pharmaceuticals, Inc. has a 12-month low of $736.01 and a 12-month high of $1,211.20. The stock has a market cap of $81.69 billion, a price-to-earnings ratio of 18.40, a PEG ratio of 2.86 and a beta of 0.15. The business has a 50 day moving average of $961.76 and a 200-day moving average of $1,030.14. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09.

Insider Activity

In other news, CFO Christopher R. Fenimore sold 5,680 shares of the firm’s stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the sale, the chief financial officer now directly owns 15,305 shares of the company’s stock, valued at $18,447,575.65. This trade represents a 27.07 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Insiders own 7.48% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.